AbbVie Inc. announced Monday that it will acquire Gilgamesh Pharmaceuticals’ treatment for major depressive disorder in a deal valued at up to $1.2 billion.
The acquisition aims to strengthen AbbVie’s portfolio in neurological treatments, following setbacks with its experimental schizophrenia drug acquired through an $8.7 billion purchase of Cerevel Therapeutics, which failed in two mid-stage trials last year, News.Az reports, citing Reuters.
Since 2023, AbbVie has spent over $20 billion on acquisitions as its flagship rheumatoid arthritis drug, Humira, lost patent protection, prompting the company to expand its pipeline through strategic buys.
